Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci

Vanthida Huang, William J. Brown, Michael J. Rybak
Vanthida Huang
1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences
2Detroit Receiving Hospital, Detroit, Michigan 48201
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Brown
3Detroit Medical Center Laboratory
4School of Medicine, Wayne State University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Rybak
1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences
2Detroit Receiving Hospital, Detroit, Michigan 48201
4School of Medicine, Wayne State University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.rybak@wayne.edu
DOI: 10.1128/AAC.48.7.2719-2723.2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We examined the activity of CB-181963, a novel cephalosporin, against methicillin-resistant Staphylococcus aureus (MRSA) (n = 200), methicillin-susceptible S. aureus (MSSA) (n = 50), glycopeptide-intermediate Staphylococcus species (GISS) (n = 47), and VRSA (n = 2) isolates. CB-181963 exhibited MIC profiles similar to those of linezolid against MRSA and GISS; however, activity against MSSA was similar to that of vancomycin. Time-kill study results of investigations of activity against MRSA, MSSA, and GISS at 24 h were as follows: CB-181963 activity = vancomycin activity > linezolid activity (P < 0.001); CB-181963 = quinupristin-dalfopristin = vancomycin > linezolid (P < 0.05); CB-181963 > linezolid (P = 0.003); and CB-181963 = quinupristin-dalfopristin = vancomycin. CB-181963 may provide an alternative treatment for multidrug-resistant staphylococci.

The incidence of methicillin-resistant Staphylococcus aureus (MRSA) has been increasing at an alarming rate since it was first reported in the 1960s (21). In 1996, the first report of a glycopeptide-intermediate susceptible S. aureus (GISA) was described in Japan (4). Since then, other cases of GISA infections have been reported worldwide (1, 2, 3, 4, 5, 8, 13, 16, 17, 20, 22, 24, 25, 27). These GISA strains are generally found in patients who been exposed to long-term vancomycin therapy with drug MICs of >4 and <32 μg/ml. Heterogeneous GISA (hGISA) and heterogeneous glycopeptide-intermediate Staphylococcus species (hGISS) are defined as those for which vancomycin MICs are 1 to 4 μg/ml but which contain subpopulations that can grow on agar plates supplemented with vancomycin (4 μg/ml) (2). These strains were first described by Hiramatsu et al. and may be the first step in the development of GISA strains (2). Recently, the first two vancomycin-resistant S. aureus (VRSA) strains (from a Michigan and Pennsylvania patient, respectively) were reported in June and September of 2002, which increased the need to find alternative agents (6, 7).

The ideal cephalosporin compound against MRSA would combine the characteristics of high-level affinity for PBP 2a and stability against degradation by staphylococcal β-lactamase (9, 15, 18). This has been the driving factor for developing cephalosporins with activity against MRSA.

CB-181963 (Fig. 1) is a novel parenteral investigational cephalosporin belonging to the azomethine subclass of cephalosporins that has demonstrated in vitro bactericidal activity against a range of pathogens, including MRSA (Cubist Pharmaceuticals, Lexington, Mass.; D. Damphousse, D. Dvorchik, D. Benziger, and K. Galil, Abstr. 13th Eur. Cong. Clin. Microbiol. Infect. Dis., abstr. P792, 2003; and J. Silverman, N. Cotroneo, V. Laganas, G. Thorne, J. Alder, Abstr. 13th Eur. Cong. Clin. Microbiol. Infect. Dis., abstr. P793, 2003). CB-181963 displays strong binding to altered PBP 2a (Silverman et al., 13th ECCMID, abstr. P793). In vitro, CB-181963 demonstrated marked efficacy against MRSA, Klebsiella pneumoniae, Streptococcus pneumoniae, and Escherichia coli (R. Cha, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. E2011, 2003; Silverman et al., 13th ECCMID, abstr. P793). CB-181963 was noted to have a spectrum and safety profile similar to that of ceftriaxone, with additional activity against MRSA and Enterococcus faecalis reported from human and animal studies completed thus far (Cubist Pharmaceuticals; Silverman et al., 13th ECCMID, abstr. P793). The compound pharmacokinetics from initial human experience suggested that CB-181963 has elimination half-life mean values of 1.61 to 1.68 h and would be administered parenterally in the range of 500 to 1,000 mg twice daily (Damphousse et al., Abstr. 13th ECCMID, abstr. P792). A dose of 500 mg results in a maximum concentration of drug in serum of 37.3 ± 1.6 mg/ml, and a dose of 1,000 mg results in a maximum concentration of drug in serum of 72.0 ± 14.8 mg/ml; serum was maintained above the MIC (Damphousse et al., Abstr. 13th ECCMID, abstr. P792).

The aim of this study was to evaluate the activity of CB-181963 against MRSA, MSSA, GISS, and VRSA compared to that of vancomycin, linezolid, and quinupristin-dalfopristin.

(A portion of this work was presented at the 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland, May 2003, and the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., September 2003.)

There were a total of 297 clinical strains: 200 clinical strains of MRSA, 50 clinical strains of MSSA, and 47 clinical strains of GISS. GISS consisted of 35 strains of S. aureus (14 GISA strains [MIC = 8 μg/ml] and 21 hGISA strains [MIC = 4 μg/ml]), 8 strains of Staphylococcus epidermidis (6 GISS strains [MIC = 8 μg/ml] and 2 hGISS strains [MIC = 4 μg/ml]), and 4 strains of Staphylococcus haemolyticus (3 GISS strains [MIC = 8 μg/ml] and 1 hGISS strain [MIC = 4 μg/ml]). MRSA and MSSA strains were obtained from Detroit Medical Center, Detroit, Michigan, and William Beaumont Hospital, Royal Oak, Michigan. A total of 47 clinical strains of GISS were obtained from Keiichi Hiramatsu (Tokyo, Japan), the Centers for Disease Control and Prevention, the Detroit Medical Center, and the Network on Antimicrobial Resistance in S. aureus program. Two clinical strains of VRSA, including Michigan and Pennsylvania strains (VRSA-MI and VRSA-PA), were obtained from the Detroit Medical Center Laboratory from William J. Brown and from the Network on Antimicrobial Resistance in S. aureus program. ATCC 25923, a standard reference strain which is oxacillin susceptible, was used as a control.

CB-181963 (Cubist Pharmaceuticals) and quinupristin-dalfopristin (Aventis Pharmaceuticals Inc., Bridgewater, N.J.) were obtained from their respective manufacturers. Vancomycin analytical powder was commercially purchased from Sigma Chemical Company, St. Louis, Mo. Linezolid (Pharmacia, Kalamazoo, Mich.) was obtained commercially.

Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) supplemented with calcium (25 mg/liter) and magnesium (12.5 mg/liter) (SMHB) was used for all broth microdilution susceptibility testing and selective time-kill experiments. Tryptic soy agar (TSA; Difco Laboratories) for MRSA isolates and brain heart infusion (BHI) agar (Becton-Dickinson, Sparks, Md.) for GISS and VRSA isolates were used for bacterial quantification of samples from time-kill experiments.

MICs and minimum bactericidal concentrations (MBCs) were determined in duplicate using a microdilution technique in accordance with the National Committee for Clinical Laboratory Standards (23).

Selective time-kill experiments using four strains each of MRSA, MSSA, GISS, and VRSA were performed in triplicate. All drugs were tested at two to four times the MIC for MRSA, MSSA, GISS, and VRSA strains. However, against VRSA strains vancomycin was tested at a fixed concentration of 30 μg/ml. Three to five colonies from overnight growth on TSA at 37°C were added to normal saline and adjusted to produce a 0.5 McFarland standard suspension of organisms. This suspension was diluted with SMHB to achieve an inoculum of 106 CFU/ml. A 0.2-ml suspension of each organism was added to 1.8 ml of SMHB with a 0.1-ml stock solution of each antibiotic in a 24-well tissue culture plate (final volume, 2.0 ml per well). Culture wells were incubated at 37°C with constant shaking for 24 h. Sample aliquots (0.1 ml) were removed from cultures at 0, 8, and 24 h. Antimicrobial carryover was minimized by serial dilution (10- to 10,000-fold) of plated samples in conjunction with vacuum filtration, in which samples were washed through a 0.45-μm-pore-size micron filter with normal saline. These filters were then plated onto TSA or BHI agar and incubated to confirm colony counts. Colony counts were determined by plating 50 μl of each diluted sample onto TSA and BHI plates with an automated spiral dispenser (WASP; Don Whitley Scientific Limited, West Yorkshire, England). We determined these methods to have a lower limit of reliable detection of 2.0 log10 CFU/ml. Growth control wells for each organism were prepared without antibiotic and run in parallel to the antibiotic test wells. Bactericidal activity was defined as a reduction of 3 log10 CFU/ml (99.9% killing) in bacterial density from the starting inoculum. Time to 99.9% killing was determined by linear regression of the sample points when r2 ≥ 0.95 or by visual inspection.

All statistical analyses were performed using SPSS statistical software (release 11.5; SPSS, Inc. Chicago, Ill.). Colony counts at 24 h and time to 99.9% killing were compared between groups by use of one-way analysis of variance followed by Tukey's post hoc test for multiple comparisons. A P value of ≤0.05 indicated statistical significance.

The drug activities for the 200 clinical strains of MRSA, 50 clinical strains of MSSA, 47 clinical strains of GISS, and 2 clinical strains of VRSA are reported in Table 1. The levels of activity of CB-181963 against all clinical strains (MRSA, MSSA, GISS, and VRSA) indicated equivalent levels of potency. CB-181963 activity against MRSA and VRSA was equal to that of linezolid; CB-181963 activity levels were twofold higher against MSSA and twofold lower against GISS. CB-181963 was four- to eightfold less active than quinupristin-dalfopristin against MRSA, MSSA, GISS, and VRSA. However, quinupristin-dalfopristin was 2-, 16-, 128-, and 2,048-fold more active than vancomycin against MRSA and MSSA, GISS, VRSA-MI, and VRSA-PA, respectively. CB-181963 demonstrated similar levels of activity against MRSA and GISS strains, with significant activity against the MSSA strains. There were two clinical strains of GISS for which the CB-181963 MIC was 8 μg/ml. The MBC and MIC results demonstrated that CB-181963 possessed bactericidal activity against MRSA, MSSA, GISS, and VRSA. The time-kill mean results of the four randomly selected strains of MRSA, MSSA, and GISS as well as those of two VRSA strains are shown in Fig. 2. At concentrations four times the MIC, CB-181963 and vancomycin achieved 99.9% killing against MRSA in 8 h, which was higher than the level of killing observed with linezolid and quinupristin-dalfopristin. The bactericidal activity of CB-191863 and vancomycin was maintained for up to 24 h. Against MRSA at 8 and 24 h, CB-181963 and vancomycin were significantly more active than linezolid (P < 0.001). Linezolid and quinupristin-dalfopristin activities against MRSA at 24 h were not significantly different. In addition, the relative bactericidal activity of quinupristin-dalfopristin against MRSA at 24 h was not significantly different from those of CB-181963 and vancomycin. CB-181963 and quinupristin-dalfopristin (P < 0.001) achieved 99.9% killing against MSSA in 8 h at concentrations four times the MIC, which was higher than the level of killing observed with linezolid and vancomycin. This bactericidal activity was maintained up to 24 h for CB-181963 and quinupristin-dalfopristin. CB-181963, quinupristin-dalfopristin, and vancomycin were significantly more active against MSSA than linezolid (P < 0.05) at 8 and 24 h. The activities of CB-181963, quinupristin-dalfopristin, and vancomycin against MSSA at 24 h were not significantly different. At concentrations two times the MIC, CB-181963 achieved 99.9% killing against GISS at 24 h, which was higher than the level of killing observed with linezolid (P = 0.003). However, the activities of CB-181963, quinupristin-dalfopristin, and vancomycin were not significantly different at 24 h. CB-181963 and quinupristin-dalfopristin at two times the MIC demonstrated bactericidal activity against VRSA-MI at 24 h. However, only CB-181963 achieved 99.9% killing against VRSA-PA at 24 h, which was higher than the level of killing observed with quinupristin-dalfopristin and vancomycin (P < 0.01).

CB-181963 is a new parenteral cephalosporin with potent in vitro activity against a broad range of gram-positive pathogens, including methicillin-susceptible and -resistant S. aureus. The spectrum of activity extends to GISS and VRSA as well as a variety of gram-negative pathogens. CB-181963 is one of a number of cephalosporins, such as Ro 63-9141 (BAL9141), RWJ-54428 (MC-02479), and S-3578, with various degrees of activity against MRSA (10, 11, 12, 14, 18, 19, 26, 28; Damphousse et al., Abstr. 13th ECCMID, abstr. P792; Silverman et al., 13th ECCMID, abstr. P793).

The incidence of MRSA strains, as well as that of multidrug-resistant staphylococci, has greatly increased (21). Cephalosporins have been widely used in infection therapy because of their broad-spectrum antibacterial activity and lower frequency of side effects. However, their efficacy against MRSA has been insufficient to eradicate infections caused by the pathogens. Therefore, a search for cephalosporin derivatives with potent activity against MRSA is an option to be explored. CB-181963 has demonstrated potent in vitro activity against MRSA (Silverman et al., 13th ECCMID, abstr. P793). In the present study, the susceptibility of clinical staphylococcal isolates, including MRSA, MSSA, GISS, and VRSA isolates, was examined. Our data further established that CB-181963 has potent antistaphylococcal activity in vitro (D. C. Draghi, C. Thornsberry, D. F. Sahm, J. A. Karlowsky, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-544, 2003; Silverman et al., 13th ECCMID, abstr. P793). Although CB-181963 had a slightly higher MIC than vancomycin, the bactericidal activity was equal to and greater than that of vancomycin, linezolid, and quinupristin-dalfopristin against MRSA and GISS, respectively. These results indicate that CB-181963 is a novel cephalosporin derivative that demonstrates activity against susceptible and multidrug-resistant staphylococci. CB-181963 may provide an alternative option for the treatment of MRSA infections. However, further pharmacokinetic and pharmacodynamic, as well as clinical investigations, are warranted to determine its ultimate place in therapy versus presently available options.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

CB-181963 chemical structure.

  • Open in new tab
  • Download powerpoint
  • Open in new tab
  • Download powerpoint
FIG. 2.

Time-kill experiments at four times the MIC for a combination of four selected clinical MRSA strains (A), four times the MIC for four selected clinical MSSA strains (B), two times the MIC for a combination of four selected clinical GISS strains (including three S. aureus and one S. epidermidis strains; the drug MIC for all strains was 8 μg/ml) (C), and two times the MIC for clinical strains of VRSA-MI and VRSA-PA (D and E). Results represent means ± standard deviations. GC, growth control; C, CB-181963; L, linezolid; Q-D, quinupristin-dalfopristin; V, vancomycin.

View this table:
  • View inline
  • View popup
TABLE 1.

Activities of CB-181963, linezolid, quinupristin-dalfopristin, and vancomycin against clinical strains of MRSA, MSSA, GISS, and VRSAa

ACKNOWLEDGMENTS

This project was supported by grants from Cubist Pharmaceuticals.

FOOTNOTES

    • Received 6 October 2003.
    • Returned for modification 12 November 2003.
    • Accepted 12 March 2004.
  • Copyright © 2004 American Society for Microbiology

REFERENCES

  1. 1.↵
    Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, T. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet353:1587-1588.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Bert, F., J. Clarissou, F. Durand, D. Delefosse, C. Chauvet, P. Lefebvre, N. Lambert, and C. Branger. 2003. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J. Clin. Microbiol.41:5147-5152.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Bierbaum, G., K. Fuchs, W. Lenz, and H.-G. Sahl. 1999. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur. J. Clin. Microbiol. Infect. Dis.18:691-696.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Centers for Disease Control and Prevention. 1996. Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan 1996. Morb. Mortal. Wkly. Rep.46:624-626.
    OpenUrl
  5. 5.↵
    Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb. Mortal. Wkly. Rep.46:765-766.
    OpenUrlPubMed
  6. 6.↵
    Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin—United States, 2002. Morb. Mortal. Wkly. Rep.51:565-567.
    OpenUrlPubMed
  7. 7.↵
    Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. Morb. Mortal. Wkly. Rep.51:902.
    OpenUrlPubMed
  8. 8.↵
    Chesneau, O., A. Morvan, and N. El Solh. 2000. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J. Antimicrob. Chemother.45:887-890.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Collins, J. K., J. Y. Mader, and M. T. Kelly. 1983. Resistance of methicillin-resistant Staphylococcus aureus to third-generation cephalosporins. J. Infect. Dis.147:591.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother.46:171-177.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Fujimura, T., Y. Yamano, I. Yoshida, J. Shimada, and S. Kuwahara. 2003. In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob. Agents Chemother.47:923-931.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Fung-Tomc, J. C., J. Clark, B. Minassian, M. Pucci, Y.-H. Tsai, E. Gradelski, L. Lamb, I. Medina, E. Huczko, B. Kolek, S. Chaniewski, C. Ferraro, T. Washo, and D. P. Bonner. 2002. In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob. Agents Chemother.46:971-976.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Guerin, F., A. Buu-Hoi, J. L. Mainardi, G. Kac, N. Colardelle, S. Vaupre, L. Gutmann, and I. Podglajen. 2000. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J. Clin. Microbiol.38:2985-2988.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Hanaki, H., H. Akagi, Y. Masaru, T. Otani, A. Hyodo, and K. Hiramatsu. 1995. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.39:1120-1126.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother.45:825-836.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet350:1670-1673.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother.40:135.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Johnson, A. P., M. Waner, M. Carter, and D. M. Livermore. 2002. In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci. Antimicrob. Agents Chemother.46:321-326.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother.50:915-932.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Kim, M. N., S. H. Hwang, Y. J. Pyo, H. M. Mun, and C. H. Pai. 2002. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J. Clin. Microbiol.40:1376-1380.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Maple, P. A. C., J. M. T. Hamilton-Miller, and W. Brumfitt. 1989. World-wide spread antibiotic-resistance in methicillin-resistant Staphylococcus aureus. Lanceti:537-540.
    OpenUrl
  22. 22.↵
    Marchese, A., G. Balistreri, E. Tonoli, E. A. Debbia, and G. C. Schito. 2000. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J. Clin. Microbiol.38:866-869.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    National Committee for Clinical Laboratory Standards. 2002. Methods for determining bactericidal activity of antimicrobial agents. NCCLS document M-26. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  24. 24.↵
    Rybak, M. J., and R. L. Akins. 2001. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs61:1-7.
    OpenUrl
  25. 25.↵
    Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med.340:493-501.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Swenson, J. M., and F. C. Tenover. 2002. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother.49:845-850.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Trakulsomboon, S., S. Danchaivijitr, Y. Rongrungruang, C. Dhiraputra, W. Susaemgrat, T. Ito, and K. Hiramatsu. 2001. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J. Clin. Microbiol.39:2439-2444.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Tsuji, M., M. Takema, H. Miwa, J. Shimada, and S. Kuwahara. 2003. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob. Agents Chemother.47:2507-2512.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci
Vanthida Huang, William J. Brown, Michael J. Rybak
Antimicrobial Agents and Chemotherapy Jun 2004, 48 (7) 2719-2723; DOI: 10.1128/AAC.48.7.2719-2723.2004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci
Vanthida Huang, William J. Brown, Michael J. Rybak
Antimicrobial Agents and Chemotherapy Jun 2004, 48 (7) 2719-2723; DOI: 10.1128/AAC.48.7.2719-2723.2004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
cephalosporins
glycopeptides
methicillin resistance
Staphylococcus aureus

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596